16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and cell culture studies suggest inhibiting MGMT or its downstream mediator USP17L2 alone or in combination with HDAC inhibitors could help treat ovarian cancer. In patients, high tumor expression of...
23:05 , Feb 1, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Fiscal 2Q; (C) During trading hours in Europe; premarket on U.S. exchange Company Date...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
20:48 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest the HDAC inhibitor entinostat alone or in combination with chemotherapy could help treat alveolar rhabdomyosarcoma. In an orthotopic mouse model of alveolar rhabdomyosarcoma, entinostat decreased tumor growth compared with vehicle,...
23:22 , Dec 14, 2018 |  BC Extra  |  Company News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The agency...
18:56 , Nov 16, 2018 |  BC Week In Review  |  Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said...
16:01 , Nov 16, 2018 |  BC Week In Review  |  Company News

MEI Pharma outlicenses PI3K inhibitor to Kyowa in Japan, BeiGene in China

MEI Pharma Inc. (NASDAQ:MEIP) granted Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) exclusive rights in Japan to develop and commercialize ME-401, initially for relapsed or refractory follicular lymphoma. ME-401 is a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor....
22:33 , Nov 15, 2018 |  BC Innovations  |  Translation in Brief

The bystander effect of Treg depletion

Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented...